COCRYSTAL PHARMA, INC. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
COCRYSTAL PHARMA, INC. (COCP) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.01 per share for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-11-18.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2013-11-18
- COCRYSTAL PHARMA, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2013-09-30 was $0.01.
- COCRYSTAL PHARMA, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2012-09-30 was $0.00.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month |
|---|---|---|
| 2013-09-30 | $0.01 10-Q · filed 2013-11-18 | $0.01 10-Q · filed 2013-11-18 |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-18 | $0.00 10-Q · filed 2013-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |